

WORLDWIDE REGISTRATION

Dolutegravir 5 mg Dispersible Tablets

APPROVAL

Australia Malawi
Botswana Namibia
Brazil Switzerland
Canada Tanzania

Chile United Kingdom

EU USA
Ghana Uruguay
Kazakhstan Zimbabwe

SUBMISSION

Argentina Mexico Burkina Faso Niger

China Singapore
Colombia South Africa
Cote d'Ivoire Thailand
DRC Turkey
Ecuador Uganda
Ethiopia Zambia

Gabon Israel Kenya

- "Approval" means: Marketing Authorisation has been granted by a country or there is no formal regulatory process in place, in the relevant country.
- "Submission" means: A registration dossier has been submitted to local authority for review in the relevant country. Please note, Submission does not guarantee that a Marketing Authorisation will be granted.
- Granted Marketing Authorisations may include limitations on the use of the product.

This document was prepared on 18 Mar 2022 and will be updated on a quarterly basis by ViiV Healthcare. It is made available for information purposes only and ViiV Healthcare accepts no liability arising from the reliance by third parties, on the information provided.